Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for preparing 5-hydroxy-7-azaindole

A technology of azaindole and hydroxyl, which is applied in the field of preparation of 5-hydroxy-7-azaindole, can solve the problems of inconvenient industrial scale-up operation, easy volatilization of boron tribromide, large amount of sodium methoxide, etc. Friendly, low cost, high yield effect

Inactive Publication Date: 2017-12-05
PHARMA SHANGHAI
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, the amount of sodium methoxide in this route is too large, and a lot of waste water is generated after treatment; in addition, boron tribromide is easy to volatilize and has high toxicity, which is not convenient for industrial scale-up operation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing 5-hydroxy-7-azaindole
  • Method for preparing 5-hydroxy-7-azaindole
  • Method for preparing 5-hydroxy-7-azaindole

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Step S1: Preparation of 5-bromo-1-(triisopropylsilyl)-pyrrolo[2,3-b]pyridine (Ⅱ / TIPS)

[0050]

[0051] At room temperature, add 400 ml of tetrahydrofuran to a 1 L three-necked flask and start stirring. Add 5-bromo-7-azaindole (30 g, 0.15 mol) and potassium tert-butoxide (25.6 g, 0.23 mol) into the reaction flask, stir to dissolve, cool down in an ice-salt bath, and wait until the internal temperature is 0°C. The dropwise addition of triisopropylchlorosilane (30.8 g, 0.16 mol) diluted with 80 ml tetrahydrofuran was started. After the addition, keep at 0-5°C for 10-20 minutes.

[0052] Control in TLC, and the reaction ends. Add 300ml of water to the reaction bottle, stir for 15 minutes and then separate the liquids, extract the aqueous phase with methyl tert-butyl ether (200ml*2), combine the organic phases, wash the organic phase once with 500ml of saturated sodium chloride aqueous solution, and separate the liquids. After drying with anhydrous sodium sulfate, con...

Embodiment 2

[0062] Step S1: Preparation of 5-bromo-1-(tert-butoxycarbonyl)-pyrrolo[2,3-b]pyridine (Ⅱ / Boc)

[0063]

[0064] At room temperature, add 500 ml of dichloromethane into a 1 L three-necked flask and start stirring. Add 5-bromo-7-azaindole (50g, 0.25mol), 4-dimethylaminopyridine DMAP (1.55g, 13mmol), triethylamine TEA (77g, 0.76mol) in reaction flask, stir to dissolve clear Afterwards, replace with nitrogen, cool down in an ice-salt bath, and start to add di-tert-butyl dicarbonate (60.93 g, 0.28 mol) dropwise when the internal temperature is 0°C. After the addition, keep the temperature at 0-5°C for 1.5 hours.

[0065] Control in TLC, and the reaction ends. Add 500ml of water to the reaction flask, stir for 15 minutes, then separate the liquids, wash the organic phase with 500 ml of water, separate the liquids, dry the organic phase over anhydrous sodium sulfate, concentrate the solvent to obtain a crude product, and obtain the compound of formula II after purification.

[...

Embodiment 3

[0074] Step S1: Preparation of 5-bromo-1-(triisopropylsilyl)-pyrrolo[2,3-b]pyridine (Ⅱ / TIPS)

[0075]

[0076] At room temperature, add 4 L of tetrahydrofuran to a 10 L four-neck flask and start stirring. Add 5-bromo-7-azaindole (300 g, 1.5 mol) and potassium tert-butoxide (256 g, 2.3 mol) into the reaction flask, stir to dissolve, cool down in an ice-salt bath, and wait until the internal temperature is 0°C, start Triisopropylchlorosilane (308 g, 1.6 mol) diluted with 800 ml tetrahydrofuran was added dropwise. After the addition, keep at 0-5°C for 10-20 minutes.

[0077] Control in TLC, and the reaction ends. Add 3L of water to the reaction flask, stir for 15 minutes, then separate the liquids, extract the aqueous phase with methyl tert-butyl ether (2L*2), combine the organic phases, wash the organic phase once with 5L of saturated sodium chloride aqueous solution, and separate the liquids. After drying with anhydrous sodium sulfate, concentrate the solvent to obtain an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for preparing 5-hydroxy-7-azaindole. The intermediate structure is shown in the formula III. The method comprises that a compound 5-bromo-7-azaindole shown in the formula I as a raw material undergoes a nitrogen protection reaction and a hydroxylation and direct deprotection reaction to produce 5-hydroxy-7-azaindole shown in the formula III. The method utilizes cheap and easily available raw materials, realizes a low cost, is used under mild reaction conditions, has a high yield and is suitable for industrial large-scale production.

Description

technical field [0001] The invention belongs to the technical field of organic synthesis, and in particular relates to a preparation method of 5-hydroxyl-7-azaindole. Background technique [0002] ABT-199 (Venetoclax), chemical name 2-[(1H-pyrrolo[2,3-B]pyridin-5-yl)oxy]-4-[4-[[2-(4-chlorophenyl) -4,4-Dimethylcyclohex-1-enyl]methyl]piperazin-1-yl]-nitrogen-[3-nitro-4-[[(tetrahydropyran-4-yl)methyl Base]amino]benzenesulfonamide]methylbenzoate is an experimental B-cell lymphoma factor-2 (BCL-2) inhibitor jointly developed by AbbVie and Roche. BCL-2 is a protein that prevents apoptosis in some cells, including lymphocytes. ABT-199 is designed to selectively inhibit the function of BCL-2 factors, restore the cell communication system, and allow cancer cells to self-destruct, so as to achieve the effect of treating tumors. [0003] [0004] FDA believes that this drug has a significant effect in the treatment of chronic myelogenous leukemia patients with 17p gene deletion m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D471/04
CPCY02P20/55C07D471/04
Inventor 庄银枪彭少平江辉
Owner PHARMA SHANGHAI